First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2021-11-06
Target enrollment:
Participant gender:
Summary
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy.
This study is the first time GFB-024 has been used in humans. The first part of the study
will assess the safety of a single dose of GFB-024 in healthy overweight and obese volunteers
and the effect of GFB-024 on the body as compared to an inactive placebo medication. The
second part of the study will assess the safety of repeated doses of GFB-024 in participants
with Type 2 diabetes and the effect of GFB-024 on the body as compared to an inactive placebo
medication.